FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155495810> ?p ?o ?g. }

• W2155495810 endingPage "663" @default.
• W2155495810 startingPage "659" @default.
• W2155495810 abstract "HomeCirculationVol. 107, No. 5Evaluation and Management of Diastolic Heart Failure Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBEvaluation and Management of Diastolic Heart Failure Brad G. Angeja, MD and William Grossman, MD Brad G. AngejaBrad G. Angeja From the Cardiovascular Division, Department of Medicine, the University of California, San Francisco. Search for more papers by this author and William GrossmanWilliam Grossman From the Cardiovascular Division, Department of Medicine, the University of California, San Francisco. Search for more papers by this author Originally published11 Feb 2003https://doi.org/10.1161/01.CIR.0000053948.10914.49Circulation. 2003;107:659–663Case presentation: A 73-year-old female smoker with a history of hypertension presents to the emergency room with dyspnea on exertion for 2 weeks, now progressing to shortness of breath at rest for 1 day. She has no angina, but has 2-pillow orthopnea and possible paroxysmal nocturnal dyspnea. On examination, blood pressure is 180/96 mm Hg, heart rate is 95 beats per minute and regular, and she is afebrile. Jugular venous pressure is 11 cm, and there are rales in the lower third of both lung fields. On cardiac auscultation there is an S4, but no S3 or murmur. On chest radiography, emphysematous changes are present, and there are patchy bilateral infiltrates consistent with pulmonary edema or pneumonia. Heart size is mildly increased. Is she suffering from congestive heart failure, and if so, why? What are the best management options acutely and after hospital discharge?OverviewCongestive heart failure (CHF) is one of the most common reasons for hospital admission in the United States. The syndrome usually evokes images of an enlarged heart with reduced systolic function. However, perhaps 50% of patients with CHF have normal or only minimally impaired systolic dysfunction and are diagnosed with diastolic heart failure (D-CHF) by exclusion.1–4 Rather than define D-CHF by what it is not (that is, CHF without systolic dysfunction), we regard D-CHF as CHF due to increased resistance to diastolic filling of part or all of the heart. Causes of D-CHF so defined are listed in Table 1; this review will focus on the myocardial causes.5,6TABLE 1. Causes of Diastolic Congestive Heart FailureMyocardial Impaired relaxation Epicardial or microvascular ischemia Myocyte hypertrophy Cardiomyopathies Aging Hypothyroidism Increased passive stiffness Diffuse fibrosis Post-infarct scarring Myocyte hypertrophy Infiltrative (eg, amyloidosis, hemochromatosis, Fabry’s disease)Endocardial Fibroelastosis Mitral or tricuspid stenosisEpicardial / Pericardial Pericardial constriction Pericardial tamponadeCoronary microcirculation Capillary compression Venous engorgementOther Volume overload of the contralateral ventricle Extrinsic compression by tumorDepending on the cohort studied and the exact definition, the prevalence of D-CHF increases with age and is higher in women than men. Hypertension and left ventricular hypertrophy (LVH) are common. Compared with classic systolic CHF (S-CHF), the prognosis is unclear, but long-term mortality may be similar, especially in older patients.7,8PathophysiologyImpaired RelaxationImpaired diastolic filling is the first manifestation of active ischemia, and evidence in animals and humans confirms that demand ischemia results in an upward shift of the left ventricular diastolic pressure-volume relationship.9 Decreased levels or activity of the sarcoplasmic reticulum calcium ATP-ase pump (SERCA) can slow the removal of calcium from the cytosol. Increased levels or activity of phospholamban, the naturally occurring SERCA-inhibitory protein, can also impair relaxation. Increased cAMP, resulting from β-adrenergic stimulation or inhibition of cardiac phosphodiesterase, phosphorylates phospholamban to remove its inhibitory effect on SERCA. The net effect is an improvement in diastolic relaxation. Because the ability of SERCA to remove calcium from the cytosol in diastole is energy-dependent, it is not surprising that ischemia leads to impaired relaxation. Pathological LVH secondary to hypertension or aortic stenosis results in decreased SERCA and increased phospholamban, again leading to impaired relaxation. Similar changes are seen in the myocardium of patients with hypertrophic or dilated cardiomyopathy. Interestingly, levels of SERCA decrease with age, coincident with impaired diastolic function.10 In addition, hypothyroidism decreases SERCA and increases phospholamban, leading to impaired relaxation; the opposite effects occur with hyperthyroidism to accelerate relaxation. Animal experiments using gene transfer,11 captopril, and β-agonists have shown that increasing the action of SERCA (or decreasing the action of phospholamban) improves diastolic relaxation.Increased Passive StiffnessIn addition to the active relaxation process, the left ventricle also has passive compliance and becomes stiffer with age. This seems to be due in part to diffuse fibrosis, as revealed by pathological studies and also by measuring serum markers of collagen turnover. Procollagen type I C-terminal propeptide is released during the synthesis of collagen type I, and serum concentrations seem to be increased in cardiac fibrosis.12 Passive stiffness is also increased in patients with focal scar or aneurysm after myocardial infarction. Myocyte hypertrophy can increase passive as well as active stiffness. Infiltrative cardiomyopathies such as amyloidosis increase passive myocardial stiffness and impair diastolic function in a similar fashion.Endocardial and Pericardial DisordersEndocardial fibroelastosis, mitral stenosis, and pericardial constriction or tamponade cause increased resistance to diastolic filling of part or all of the heart.Microvascular Flow, Myocardial TurgorOnce LVH has occurred and LV diastolic pressure begins to rise, myocardial ischemia may play a role in worsening D-CHF, even without significant coronary stenoses. Extravascular compression caused by high LV diastolic pressure acts mainly on capillaries and small resistance coronary vessels, perhaps disrupting autoregulation and the ability to vasodilate.13 Indeed, the presence of LVH in hypertensive patients has been associated with impaired coronary flow reserve as compared with patients without LVH. Replacement of stenotic aortic valves has been associated with LVH regression and coincident improvement in coronary flow reserve. Thus, some combination of LVH and high diastolic ventricular pressure may impair microvascular function and cause silent ischemia,14 thereby worsening D-CHF. Myocardial turgor, resulting from engorgement of the microvasculature with blood, can cause an increase in diastolic stiffness. Clinically, this most likely occurs in association with right heart failure, as increased right atrial pressure leads to coronary venous engorgement.15Neurohormonal RegulationAn upregulated renin-angiotensin system contributes to D-CHF not only through development of hypertension but also via impaired myocardial relaxation.16–18 Both angiotensin II and endothelin contribute to LVH. In a rat model, the transition to D-CHF in hypertrophied hearts was also associated with “overdrive” of gene expression of endothelin and B-type natriuretic peptide.19 Abnormal diastolic function correlates with reduced heart rate variability, suggesting autonomic imbalance.20DiagnosisThe diagnosis of D-CHF is usually a clinical one: the presence of symptoms and signs of heart failure in the setting of increased ventricular filling pressure, with normal systolic function. Ideally, there should also be objective evidence of diastolic dysfunction by echocardiography or cardiac catheterization.21 Because the specific lower limit of ejection fraction or other criteria is arbitrary, the distinction between D-CHF and S-CHF is often blurred. A complicating fact is that diastolic dysfunction frequently accompanies systolic dysfunction. In addition, D-CHF is even more difficult to identify in the compensated state. Unlike S-CHF, in which a persistently decreased ejection fraction is evident, all but a few subtle baseline abnormalities may disappear with volume and blood pressure control and relief of ischemia in patients with D-CHF.Diagnostic TestingThe diagnostic standard for D-CHF is cardiac catheterization, which demonstrates increased ventricular diastolic pressure with preserved systolic function and normal ventricular volumes. The pressures in cardiac chambers proximal to the affected ventricle are also elevated; eg, increased left atrial and pulmonary capillary wedge pressures in patients with left ventricular diastolic dysfunction. If micromanometer catheters are used, peak negative dP/dt and τ (time constant of LV relaxation) are 2 useful parameters of impaired LV diastolic relaxation.A more practical alternative is echocardiography, which can at least exclude S-CHF. Although echocardiography may not always be available in the acute setting, measurements of ejection fraction made several days after admission correlate with acute measurements in patients with acute pulmonary edema and hypertension.22 Doppler techniques can measure intracardiac blood flow and thereby infer pressures. The diastolic filling of cardiac chambers is complex, and multiple parameters have been studied.23 The most familiar of these are the mitral inflow velocities, the E and A waves that correspond to early flow during LV relaxation and the subsequent contribution from atrial contraction. Pulmonary vein flow is also measured in 2 phases, systolic and diastolic. Newer modalities that are not as well validated include color M-mode of the mitral flow propagation wave and Doppler tissue imaging (diastolic velocities of the myocardial tissue itself).Echocardiographically, normal diastolic function is characterized by predominantly early diastolic mitral flow (E wave exceeds A wave velocity). With impaired relaxation, atrial contraction contributes relatively more to ventricular filling (A wave > E wave velocity, with prolonged deceleration of the E wave, usually >240 milliseconds). This state is common with increasing age and may identify patients at risk for D-CHF. When ventricular diastolic pressure increases to the point that atrial contraction contributes little to filling, the E wave again becomes predominant but with rapid deceleration, first in a pseudonormal pattern and ultimately in a restrictive pattern (high E wave velocity, usually more than twice the A wave velocity). Both of these filling patterns are reliably associated with diastolic-dominant pulmonary vein flow in older patients (over 50 years of age). There are 2 waves of pulmonary vein flow, during systole and diastole, analogous to the x and y descents of the jugular veins. Elevated left atrial pressure impairs atrial filling during descent of the base in ventricular systole, and pulmonary vein flow occurs predominantly during diastole when the mitral valve is open. This pattern can be seen with either S-CHF or D-CHF. Echocardiography during the acute presentation of our patient might be expected to show a pseudonormal or restrictive mitral inflow pattern with diastolic-dominant pulmonary vein flow.Newer MethodsA major limitation in diagnosing D-CHF is the clinical assessment of CHF itself. Our patient’s history of smoking and her chest x-ray findings are consistent with pulmonary disease, which could also account for her symptoms and masquerade as CHF. What if her BNP level were 689 pg/mL (normal <80)? BNP has been proposed as a tool to distinguish CHF from other causes of acute dyspnea.24 This test seems to have utility in isolated D-CHF as well, distinguishing D-CHF from chronic obstructive lung disease and identifying pseudonormal and restrictive echocardiographic filling patterns with sensitivity and specificity of about 85%, using an upper limit of 62 pg/mL.25 The simplest definition of D-CHF may be an elevated BNP with normal systolic function. Because BNP increases during exercise along with LV filling pressure in CHF patients, exercise measurement of BNP might even be a provocative test to identify chronic D-CHF.26TreatmentModification of PathophysiologyIn contrast to the many clinical trials in S-CHF, there are few studies on therapy for D-CHF. Our approach to therapy of D-CHF depends on modification of the pathophysiology and is summarized in Table 2. One treatment that has obvious empirical benefit for symptom relief is volume reduction with diuretics, or with dialysis in the patient with renal failure. In addition, if the hallmark of D-CHF is impaired diastolic LV filling, then allowing the maximum time for filling to occur might be expected to relieve symptoms. Thus, rate-slowing agents are commonly used. Calcium-channel blockers and β-blockers have been shown to improve some exercise parameters and, in small studies or subgroup analyses, to reduce mortality.2 In the trial by the Digoxin Investigators Group, digoxin had similar reductions in hospitalization for CHF patients with and without systolic dysfunction; perhaps rate-slowing is the mechanism by which this benefit occurred.27 For patients in atrial fibrillation, restoration of normal sinus rhythm and an organized atrial contraction may improve diastolic filling.28TABLE 2. Current and Potential Treatments for Diastolic Congestive Heart FailurePathophysiological BasisTherapyRelieve volume overloadDiureticFluid and sodium restrictionDialysisDecrease heart rate, prolong diastolic filling timeβ-adrenergic blockadeCalcium channel blockade (verapamil or diltiazem)Consider digoxinRestore atrial contraction (atrial fibrillation)Antiarrhythmic agentsCardioversionRenin-angiotensin axis blockadeAngiotensin-converting enzyme inhibitorsAngiotensin receptor antagonistsAldosterone blockadeSpironolactoneInvestigational agentsControl hypertensionAdditional agents if neededRelieve ischemiaMedical therapyRevascularizationAs noted above, angiotensin II has deleterious effects on relaxation itself, and blockade of the renin-angiotensin system improves diastolic distensibility of the ventricle in both human and animal studies.16,17 Short-term treatment with losartan may be associated with increased exercise time, perhaps via afterload reduction.29 In addition, when LVH is a major component of D-CHF, agents associated with LVH regression might have particular benefit. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study has shown that among patients with hypertension and LVH shown by ECG, losartan reduced cardiovascular complications compared with atenonol.30 Of note, losartan has been associated with greater regression of biopsy-proven myocardial fibrosis and reduced LV chamber stiffness.31 Currently there are several multicenter, placebo-controlled, randomized trials evaluating angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and β-blockers in patients with D-CHF.2Investigational AgentsAldosterone seems to be important in the development of fibrosis, both in the remodeling of S-CHF and in the development of LVH. In the Randomized ALdactone (spironolactone) Evaluation Study for congestive heart failure (RALES), which focused on patients with S-CHF, placebo-treated patients with the highest serum levels of markers of collagen turnover had the worst prognosis, and such patients had the greatest response to spironolactone.32 Whether similar results might be observed in patients with D-CHF is not known, but the idea is attractive on pathophysiological grounds.Associated Risk FactorsIn the Framingham cohort and other databases, hypertension is the strongest risk factor for CHF, and the development of LVH is the likely segue to D-CHF in particular. Therefore, aggressive treatment to normalize blood pressure in these individuals is essential. On the basis of what we know about the pathophysiology of D-CHF, treatment of hypertension in these patients should focus on blockade of the renin-angiotensin axis, use of diuretics (especially aldosterone antagonists), and β-blockers. Finally, with the same intensity as for systolic dysfunction, the diagnosis of D-CHF should prompt a thorough workup for coronary artery disease. Ischemic episodes can cause D-CHF through impaired relaxation, which can result in flash pulmonary edema. Revascularization and medical therapy reduce symptoms and may improve survival in patients with coronary artery disease, and patients should be treated according to existing American College of Cardiology/American Heart Association guidelines.33ConclusionsAlthough clinical and echocardiographic criteria are still imperfect, a clinical presentation of CHF in a patient with preserved systolic function likely represents D-CHF. Incorporation of serum BNP measurement in practice may increase the accuracy of the diagnosis. Until further evidence is available from randomized therapeutic trials, clinicians should focus on a few general principles in the treatment of D-CHF: reduce volume overload, slow the heart rate, control hypertension, and relieve myocardial ischemia. Agents that block the renin-angiotensin system and aldosterone are particularly attractive, on the basis of pathophysiological studies.FootnotesCorrespondence to William Grossman, MD, Cardiology Division, Department of Medicine, University of California, San Francisco, 505 Parnassus Ave Box 0124, San Francisco, CA 94143-0124. E-mail [email protected] References 1 Grossman W. Defining diastolic dysfunction. Circulation. 2000; 101: 2020–2021.CrossrefMedlineGoogle Scholar2 Banerjee P, Banerjee T, Khand A, et al. Diastolic heart failure: neglected or misdiagnosed? J Am Coll Cardiol. 2002; 39: 138–141.CrossrefMedlineGoogle Scholar3 Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999; 33: 1948–1955.CrossrefMedlineGoogle Scholar4 Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients > or=65 years of age. CHS Research Group Cardiovascular Health Study. Am J Cardiol. 2001; 87: 413–419.CrossrefMedlineGoogle Scholar5 Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part I. Circulation. 2002; 105: 1387–93.CrossrefMedlineGoogle Scholar6 Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part II. Circulation. 2002; 105: 1503–1508.LinkGoogle Scholar7 Senni M, Redfield MM. Heart failure with preserved systolic function: a different natural history? J Am Coll Cardiol. 2001; 38: 1277–1282.CrossrefMedlineGoogle Scholar8 Gottdiener JS, McClelland RL, Marshall R, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. Ann Intern Med. 2002; 137: 631–639.CrossrefMedlineGoogle Scholar9 Aroesty JM, McKay RG, Heller GV, et al. Simultaneous assessment of left ventricular systolic and diastolic dysfunction during pacing-induced ischemia. Circulation. 1985; 71: 889–900.CrossrefMedlineGoogle Scholar10 Cain BS, Meldrum DR, Joo KS, et al. Human SERCA2a levels correlate inversely with age in senescent human myocardium. J Am Coll Cardiol. 1998; 32: 458–467.CrossrefMedlineGoogle Scholar11 del Monte F, Williams E, Lebeche D, et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation. 2001; 104: 1424–1429.CrossrefMedlineGoogle Scholar12 Lopez B, Gonzalez A, Varo N, et al. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension. 2001; 38: 1222–1226.CrossrefMedlineGoogle Scholar13 Watanabe J, Levine MJ, Bellotto F, et al. Left ventricular diastolic chamber stiffness and intramyocardial coronary capacitance in isolated dog hearts. Circulation. 1993; 88: 2929–2940.CrossrefMedlineGoogle Scholar14 Stern S. Angina pectoris without chest pain: clinical implications of silent ischemia. Circulation. 2002; 106: 1906–1908.LinkGoogle Scholar15 Watanabe J, Levine MJ, Bellotto F, et al. Effects of coronary venous pressure on left ventricular diastolic distensibility. Circ Res. 1990; 67: 923–932.CrossrefMedlineGoogle Scholar16 Friedrich SP, Lorell BH, Rousseau MF, et al. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation. 1994; 90: 2761–2771.CrossrefMedlineGoogle Scholar17 Schunkert H, Jackson B, Tang SS, et al. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation. 1993; 87: 1328–1339.CrossrefMedlineGoogle Scholar18 Flesch M, Schiffer F, Zolk O, et al. Angiotensin receptor antagonism and angiotensin converting enzyme inhibition improve diastolic dysfunction and Ca(2+)-ATPase expression in the sarcoplasmic reticulum in hypertensive cardiomyopathy. J Hypertens. 1997; 15: 1001–1009.CrossrefMedlineGoogle Scholar19 Yamamoto K, Masuyama T, Sakata Y, et al. Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: absence of AT1 receptor downregulation and ‘overdrive’ of the endothelin system. Cardiovasc Res. 2000; 46: 421–432.CrossrefMedlineGoogle Scholar20 Pitzalis MV, Iacoviello M, Massari F, et al. Influence of gender and family history of hypertension on autonomic control of heart rate, diastolic function and brain natriuretic peptide. J Hypertens. 2001; 19: 143–148.CrossrefMedlineGoogle Scholar21 Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. 2000; 101: 2118–2121.CrossrefMedlineGoogle Scholar22 Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001; 344: 17–22.CrossrefMedlineGoogle Scholar23 Vitarelli A, Gheorghiade M. Diastolic heart failure: standard Doppler approach and beyond. Am J Cardiol. 1998; 81: 115G–121G.CrossrefMedlineGoogle Scholar24 Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002; 39: 202–209.CrossrefMedlineGoogle Scholar25 Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 2002; 105: 595–601.CrossrefMedlineGoogle Scholar26 Matsumoto A, Hirata Y, Momomura S, et al. Effects of exercise on plasma level of brain natriuretic peptide in congestive heart failure with and without left ventricular dysfunction. Am Heart J. 1995; 129: 139–145.CrossrefMedlineGoogle Scholar27 The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med. 1997; 336: 525–533.CrossrefMedlineGoogle Scholar28 Yu CM, Wang Q, Lau CP, et al. Reversible impairment of left and right ventricular systolic and diastolic function during short-lasting atrial fibrillation in patients with an implantable atrial defibrillator: a tissue Doppler imaging study. Pacing Clin Electrophysiol. 2001; 24: 979–88.CrossrefMedlineGoogle Scholar29 Warner JG Jr, Metzger DC, Kitzman DW, et al. Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise. J Am Coll Cardiol. 1999; 33: 1567–1572.CrossrefMedlineGoogle Scholar30 Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 995–1003.CrossrefMedlineGoogle Scholar31 Diez J, Querejeta R, Lopez B, et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002; 105: 2512–2517.LinkGoogle Scholar32 Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension. 2001; 38: 1227–1232.CrossrefMedlineGoogle Scholar33 Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). Circulation. 1999; 99: 2829–2848.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Ito M, Ujihara Y, Sugita S and Nakamura M (2021) Comparison of the histology and stiffness of ventricles in Anura of different habitats, Journal of Biological Physics, 10.1007/s10867-021-09579-4, 47:3, (287-300), Online publication date: 1-Sep-2021. Bonagura J and Fuentes V (2021) Echocardiography Small Animal Diagnostic Ultrasound, 10.1016/B978-0-323-53337-9.00017-4, (230-354.e12), . Monaco F, Di Prima A, Kim J, Plamondon M, Yavorovskiy A, Likhvantsev V, Lomivorotov V, Hajjar L, Landoni G, Riha H, Farag A, Gazivoda G, Silva F, Lei C, Bradic N, El-Tahan M, Bukamal N, Sun L and Wang C (2020) Management of Challenging Cardiopulmonary Bypass Separation, Journal of Cardiothoracic and Vascular Anesthesia, 10.1053/j.jvca.2020.02.038, 34:6, (1622-1635), Online publication date: 1-Jun-2020. Patel R, Desai A, Patel P, Vanka V, Ghadiam H and Kizhakekuttu T Physician Variability in Diastology Reporting in Patients With Preserved Ejection Fraction: A Single Center Experience, Cureus, 10.7759/cureus.9062 Zhang F, Liang Y, Chen X, Xu L, Zhou C, Fan T and Yan J (2020) Echocardiographic evaluation of left ventricular end diastolic pressure in patients with diastolic heart failure, Medicine, 10.1097/MD.0000000000022683, 99:49, (e22683) Hogan C (2020) Heart Failure Emergency Department Critical Care, 10.1007/978-3-030-28794-8_12, (201-212), . Atiyah M, Kurdi A, Al Tuwaijry O, Al Sahari A, Al Rakaf M, Babic I, Al Habshan F, Alhalees Z and Al Najashi K (2020) Fetal aortic valvuloplasty: first report of two cases from Saudi Arabia, Journal of Cardiothoracic Surgery, 10.1186/s13019-020-01195-y, 15:1, Online publication date: 1-Dec-2020. Tateishi Y, Kanamoto T, Nakaoka K, Yoshimura S, Miyazaki T, Shiraishi H, Morimoto S, Tsuneto A, Maemura K, Morofuji Y, Horie N, Izumo T and Tsujino A (2019) A score using left ventricular diastolic dysfunction to predict 90-day mortality in acute ischemic stroke: The DONE score, Journal of the Neurological Sciences, 10.1016/j.jns.2019.01.021, 398, (157-162), Online publication date: 1-Mar-2019. Blackman A, Sobral Neto J, Lima M, Rodrigues T and Gomes O (2019) Assessment and clinical relevance of the dynamic parameters of ventricular repolarization in patients with grade I left ventricular diastolic dysfunction, Canadian Journal of Physiology and Pharmacology, 10.1139/cjpp-2018-0507, 97:6, (577-580), Online publication date: 1-Jun-2019. Lee J, Park S, Ryoo J, Oh C, Kang J, Mansur R, Alfonsi J, Lee Y, Shin S, McIntyre R and Jung J (2018) Sleep Duration and Quality as Related to Left Ventricular Structure and Function, Psychosomatic Medicine, 10.1097/PSY.0000000000000528, 80:1, (78-86), Online publication date: 1-Jan-2018. Krüger W (2017) Acute Heart Failure Syndromes Acute Heart Failure, 10.1007/978-3-319-54973-6_2, (81-162), . Tomita Y, Nakae I, Hayashi H, Ozawa T and Horie M (2017) Utility of Phase Standard Deviation and Histogram Bandwidth, Derived from Phase Analysis, as Clinical Indicators of Heart Failure, Annals of Nuclear Cardiology, 10.17996/anc.17-00026, 4:1, (11-22), . Krüger W (2017) Heart Failure with Normal Left Ventricular Ejection Fraction (HFNEF) Acute Heart Failure, 10.1007/978-3-319-54973-6_5, (273-339), . Gaasch W (2017) Deliberations on Diastolic Heart Failure, The American Journal of Cardiology, 10.1016/j.amjcard.2016.08.093, 119:1, (138-144), Online publication date: 1-Jan-2017. Krüger W (2017) Cardiac Physiology and Acute Heart Failure Syndromes Acute Heart Failure, 10.1007/978-3-319-54973-6_1, (1-80), . Bang J, Lee J, Sang B, Hoon Kim Y, Han D, Song J and Hwang G (2016) High Left Ventricular Filling Pressure on Doppler Echocardiography Is Associated With Graft Failure and Overall Mortality Following Kidney Transplantation, Journal of Cardiothoracic and Vascular Anesthesia, 10.1053/j.jvca.2015.10.006, 30:3, (585-591), Online publication date: 1-Jun-2016. Mishra R, Tietjens J, Regan M, Whooley M and Schiller N (2015) The Prognostic Utility of Echo-Estimated Left Ventricular End-Diastolic Pressure-Volume Relationship in Stable Coronary Artery Disease: The Heart and Soul Study, Echocardiography, 10.1111/echo.12955, 32:11, (1639-1646), Online publication date: 1-Nov-2015. Malik V, Subramanian A, Hote M and Kiran U (2015) Effect of Levosimendan on Diastolic Function in Patients Undergoing Coronary Artery Bypass Grafting, Journal of Cardiovascular Pharmacology, 10.1097/FJC.0000000000000256, 66:2, (141-147), Online publication date: 1-Aug-2015. Bonagura J and Fuentes V (2015) Echocardiography Small Animal Diagnostic Ultrasound, 10" @default.
• W2155495810 created "2016-06-24" @default.
• W2155495810 creator A5090473131 @default.
• W2155495810 creator A5091123338 @default.
• W2155495810 date "2003-02-11" @default.
• W2155495810 modified "2023-10-16" @default.
• W2155495810 title "Evaluation and Management of Diastolic Heart Failure" @default.
• W2155495810 cites W1547783254 @default.
• W2155495810 cites W1971166805 @default.
• W2155495810 cites W2014683929 @default.
• W2155495810 cites W2018522628 @default.
• W2155495810 cites W2018763145 @default.
• W2155495810 cites W2032602706 @default.
• W2155495810 cites W2053878446 @default.
• W2155495810 cites W2071078815 @default.
• W2155495810 cites W2077842562 @default.
• W2155495810 cites W2081329121 @default.
• W2155495810 cites W2085241902 @default.
• W2155495810 cites W2098605555 @default.
• W2155495810 cites W2099156846 @default.
• W2155495810 cites W2124250667 @default.
• W2155495810 cites W2133217116 @default.
• W2155495810 cites W2155014420 @default.
• W2155495810 cites W2156325087 @default.
• W2155495810 cites W2317735156 @default.
• W2155495810 cites W2323050154 @default.
• W2155495810 cites W2945068164 @default.
• W2155495810 doi "https://doi.org/10.1161/01.cir.0000053948.10914.49" @default.
• W2155495810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12578862" @default.
• W2155495810 hasPublicationYear "2003" @default.
• W2155495810 type Work @default.
• W2155495810 sameAs 2155495810 @default.
• W2155495810 citedByCount "184" @default.
• W2155495810 countsByYear W21554958102012 @default.
• W2155495810 countsByYear W21554958102013 @default.
• W2155495810 countsByYear W21554958102014 @default.
• W2155495810 countsByYear W21554958102015 @default.
• W2155495810 countsByYear W21554958102016 @default.
• W2155495810 countsByYear W21554958102017 @default.
• W2155495810 countsByYear W21554958102018 @default.
• W2155495810 countsByYear W21554958102019 @default.
• W2155495810 countsByYear W21554958102020 @default.
• W2155495810 countsByYear W21554958102021 @default.
• W2155495810 countsByYear W21554958102022 @default.
• W2155495810 countsByYear W21554958102023 @default.
• W2155495810 crossrefType "journal-article" @default.
• W2155495810 hasAuthorship W2155495810A5090473131 @default.
• W2155495810 hasAuthorship W2155495810A5091123338 @default.
• W2155495810 hasBestOaLocation W21554958102 @default.
• W2155495810 hasConcept C126322002 @default.
• W2155495810 hasConcept C164705383 @default.
• W2155495810 hasConcept C177713679 @default.
• W2155495810 hasConcept C2778198053 @default.
• W2155495810 hasConcept C2779781611 @default.
• W2155495810 hasConcept C2781374807 @default.
• W2155495810 hasConcept C57900726 @default.
• W2155495810 hasConcept C71924100 @default.
• W2155495810 hasConcept C78085059 @default.
• W2155495810 hasConcept C84393581 @default.
• W2155495810 hasConceptScore W2155495810C126322002 @default.
• W2155495810 hasConceptScore W2155495810C164705383 @default.
• W2155495810 hasConceptScore W2155495810C177713679 @default.
• W2155495810 hasConceptScore W2155495810C2778198053 @default.
• W2155495810 hasConceptScore W2155495810C2779781611 @default.
• W2155495810 hasConceptScore W2155495810C2781374807 @default.
• W2155495810 hasConceptScore W2155495810C57900726 @default.
• W2155495810 hasConceptScore W2155495810C71924100 @default.
• W2155495810 hasConceptScore W2155495810C78085059 @default.
• W2155495810 hasConceptScore W2155495810C84393581 @default.
• W2155495810 hasIssue "5" @default.
• W2155495810 hasLocation W21554958101 @default.
• W2155495810 hasLocation W21554958102 @default.
• W2155495810 hasLocation W21554958103 @default.
• W2155495810 hasOpenAccess W2155495810 @default.
• W2155495810 hasPrimaryLocation W21554958101 @default.
• W2155495810 hasRelatedWork W1964205598 @default.
• W2155495810 hasRelatedWork W1990517262 @default.
• W2155495810 hasRelatedWork W1998700507 @default.
• W2155495810 hasRelatedWork W2066491496 @default.
• W2155495810 hasRelatedWork W2092276554 @default.
• W2155495810 hasRelatedWork W2430265825 @default.
• W2155495810 hasRelatedWork W2468673710 @default.
• W2155495810 hasRelatedWork W2475222081 @default.
• W2155495810 hasRelatedWork W2965474825 @default.
• W2155495810 hasRelatedWork W2974733069 @default.
• W2155495810 hasVolume "107" @default.
• W2155495810 isParatext "false" @default.
• W2155495810 isRetracted "false" @default.
• W2155495810 magId "2155495810" @default.
• W2155495810 workType "article" @default.